Clemens Christian Cyran1, Philipp Marius
Paprottka1, Bettina Schwarz2, Steven Sourbron1,
Olaf Dietrich1, Jobst von Einem1, Rabea Hinkel3,
Christiane Bruns2, Hubertus Pietsch4, Maximilian F.
Reiser1, Bernd J. Wintersperger1, Konstantin Nikolaou1
1Institute of Clinical Radiology,
Munich University Hospitals - Campus Grosshadern, Munich, Germany; 2Department
of Surgery, Munich University Hospitals - Campus Grosshadern, Munich,
Germany; 3Department of Internal Medicine I, Munich University
Hospitals - Campus Grosshadern, Munich, Germany; 4Contrast Media
Research, Bayer Schering Pharma AG, Berlin, Germany
The
purpose of this study was to investigate the effects of sorafenib on
experimental prostate carcinomas in rats by dynamic MRI and macromolecular
contrast media (MMCM) albumin-(Gd-DTPA). Target parameters were tumor
endothelial permeability (ml/100ml/min) and tumor vascularity (%). In the
therapy group treated daily with sorafenib (10mg/kg) tumor endothelial
permeability and tumor vascularity decreased significantly (p<0.01) over
one week. Results indicate a significant effect of sorafenib on experimental
prostate carcinomas in rats. Tumor endothelial permeability and tumor
vascularity as assayed with DCE-MRI and MMCM have the potential to be applied
as non-invasive surrogate parameters of tumor response to anti-angiogenic
therapy